These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 4039984)

  • 81. High-performance liquid chromatography determination of 4'-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene beta-D-glucopyranoside) (VP 16-213) in human plasma.
    Farina P; Marzillo G; D'Incalci M
    J Chromatogr; 1981 Jan; 222(1):141-5. PubMed ID: 7217322
    [No Abstract]   [Full Text] [Related]  

  • 82. In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding.
    Liliemark EK; Liliemark J; Pettersson B; Gruber A; Björkholm M; Peterson C
    Leuk Lymphoma; 1993 Jul; 10(4-5):323-8. PubMed ID: 8220130
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
    Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
    Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration.
    Postmus PE; Holthuis JJ; Haaxma-Reiche H; Mulder NH; Vencken LM; van Oort WJ; Sleijfer DT; Sluiter HJ
    J Clin Oncol; 1984 Mar; 2(3):215-20. PubMed ID: 6321690
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Effect of different mathematical methods on etoposide area under the curve estimations and pharmacodynamic response predictions.
    McCauley DL; Lum BL; Sikic BI
    Cancer Chemother Pharmacol; 1996; 37(3):286-8. PubMed ID: 8529291
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Delayed toxicity of epipodophyllotoxin derivatives (VM 26 and VP 16-213), due to a local effect.
    Stähelin H
    Eur J Cancer (1965); 1976 Nov; 12(11):925-31. PubMed ID: 991901
    [No Abstract]   [Full Text] [Related]  

  • 87. Hypersensitivity to Etoposide in case of metastatic gestational choriocarcinoma.
    Lazović B; Milenković V; Delić M; Mazić S; Jeremic K; Hrgović Z
    Case Rep Oncol; 2013; 6(3):490-2. PubMed ID: 24163666
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.
    Wilde S; Jetter A; Rietbrock S; Kasel D; Engert A; Josting A; Klimm B; Hempel G; Reif S; Jaehde U; Merkel U; Busse D; Schwab M; Diehl V; Fuhr U
    Clin Pharmacokinet; 2007; 46(4):319-33. PubMed ID: 17375983
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations.
    Stewart CF
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S76-83. PubMed ID: 8070032
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Etoposide protein binding in cancer patients.
    Liu B; Earl HM; Poole CJ; Dunn J; Kerr DJ
    Cancer Chemother Pharmacol; 1995; 36(6):506-12. PubMed ID: 7554043
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Activity and distribution studies of etoposide and mitozolomide in vivo and in vitro against human choriocarcinoma cell lines.
    Brindley CJ; Pedley RB; Antoniw P; Newlands ES
    Cancer Chemother Pharmacol; 1987; 19(3):221-5. PubMed ID: 3581415
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Pharmacokinetics of anticancer drugs in children.
    Crom WR; Glynn-Barnhart AM; Rodman JH; Teresi ME; Kavanagh RE; Christensen ML; Relling MV; Evans WE
    Clin Pharmacokinet; 1987 Mar; 12(3):168-213. PubMed ID: 3555940
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The clinical pharmacology of etoposide and teniposide.
    Clark PI; Slevin ML
    Clin Pharmacokinet; 1987 Apr; 12(4):223-52. PubMed ID: 3297462
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.
    Holthuis JJ
    Pharm Weekbl Sci; 1988 Jun; 10(3):101-16. PubMed ID: 3047665
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The pharmacokinetics of high dose cyclophosphamide and high dose etoposide.
    Cunningham D; Cummings J; Blackie RB; McTaggart L; Banham SW; Kaye SB; Soukop M
    Med Oncol Tumor Pharmacother; 1988; 5(2):117-23. PubMed ID: 2842552
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Antineoplastic drugs in 1990. A review (Part II).
    Black DJ; Livingston RB
    Drugs; 1990 May; 39(5):652-73. PubMed ID: 2191847
    [No Abstract]   [Full Text] [Related]  

  • 97. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.
    Henwood JM; Brogden RN
    Drugs; 1990 Mar; 39(3):438-90. PubMed ID: 2184009
    [No Abstract]   [Full Text] [Related]  

  • 98. Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma.
    Chatelut E; Chevreau C; Blancy E; Lequellec A; Canal P; Roche H; Houin G; Bugat R
    Cancer Chemother Pharmacol; 1990; 26(5):365-8. PubMed ID: 2170043
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma.
    Brindley CJ; Antoniw P; Newlands ES; Bagshawe KD
    Cancer Chemother Pharmacol; 1985; 15(1):66-71. PubMed ID: 4039984
    [TBL] [Abstract][Full Text] [Related]  

  • 100. VP-16 in combinations for first-line treatment of malignant germ-cell tumors and gestational choriocarcinoma.
    Newlands ES
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):37-41. PubMed ID: 2579442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.